BioWa, Inc. Licenses Anti IL-5 Receptor Antibody from Kyowa Hakko Kogyo Co., Ltd.
Princeton, New Jersey (ots/PRNewswire) - BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment. Under the terms of the ...